Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8865243 | 0.91 | TSHR (0.38) | AKR1B1KDM1A | |
| SCHEMBL8865262 | 0.80 | KDM1A (0.47) | AKR1B1KDM1ASIGMAR1EBP | |
| SCHEMBL7609559 | 0.74 | KDM1A (0.39) | AKR1B1KDM1ASIGMAR1 | |
| SCHEMBL6316631 | 0.73 | PGR (0.47) | AKR1B1KDM1AADORA3SIGMAR1 | |
| SCHEMBL779741 | 0.71 | ADRA1A (0.39) | AKR1B1KDM1AADORA3SIGMAR1 | |
| SCHEMBL779503 | 0.71 | ADRA2A (0.46) | AKR1B1KDM1AADORA3 | |
| SCHEMBL4133169 | 0.71 | CYP3A4 (0.58) | AKR1B1KDM1AADORA3SIGMAR1 | |
| SCHEMBL7107247 | 0.71 | SIGMAR1 (0.34) | AKR1B1KDM1ASIGMAR1 | |
| SCHEMBL779687 | 0.69 | KDM1A (0.38) | KDM1ASIGMAR1EBP | |
| SCHEMBL9906167 | 0.68 | KDM1A (0.49) | KDM1AADORA3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | AKR1B1 1520/4885KDM1A 2917/4885ADORA3 272/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | AKR1B1 1491/4885KDM1A 2936/4885ADORA3 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.